Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM1UJO0)

• Drug Name: PITAVASTATIN CALCIUM Drug Info
• Synonyms: Livalo; Pitavastatin calcium; 147526-32-7; Pitavastatin hemicalcium; NK-104; Nisvastatin; UNII-IYD54XEG3W; Flovas; IYD54XEG3W; 2C25H23FNO4Ca; CHEBI:71258; NK 104 (acid); Calcium (3R,5S,E)-7-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoate; AK-50694; Itavastatin calcium; Bis((3R,5S,6E)-7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoate), monocalcium salt; Pitavastatin calcium (JAN); Alipza; Livazo; P-872441; P 872441; 6-Heptenoic acid,
• Cross-matching ID:
  PubChem CID: 5282451
  ChEBI ID: CHEMBL1237061
  CAS Number: CAS 147526-32-7
  TTD Drug ID: D0G1WL
  VARIDT Drug ID: DR00206
  INTEDE Drug ID: DR1306

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Steroid biosynthesis	2.32	0.00e+0	19/20 (95%)	MSMO1;SQLE;NSDHL;...
Steroid hormone biosynthesis	2.05	0.00e+0	43/61 (70.49%)	AKR1C1;AKR1C2;AKR1C3;...
Terpenoid backbone biosynthesis	1.98	0.00e+0	18/22 (81.82%)	HMGCS1;IDI1;FDPS;...
Glycerolipid metabolism	1.96	0.00e+0	44/61 (72.13%)	ALDH2;LPIN1;MGLL;...
PPAR signaling pathway	1.96	0.00e+0	66/74 (89.19%)	HMGCS1;FADS2;SCD;...
Histidine metabolism	1.95	0.00e+0	16/22 (72.73%)	ALDH2;ALDH3B1;ALDH3A2;...
Salivary secretion	1.90	4.63e-3	76/93 (81.72%)	LYZ;CALML5;CST3;...
Biosynthesis of unsaturated fatty acids	1.84	1.08e-2	21/27 (77.78%)	FADS2;SCD;FADS1;...
Ascorbate and aldarate metabolism	1.77	1.80e-2	15/30 (50%)	ALDH2;ALDH3A2;UGDH;...
Arrhythmogenic right ventricular cardiomyopathy	1.77	1.62e-2	70/77 (90.91%)	DSP;JUP;ITGB4;...
Metabolism of xenobiotics by cytochrome P450	1.68	4.62e-2	49/77 (63.64%)	AKR1C1;AKR7A2;CYP3A5;...
Fatty acid degradation	1.68	4.41e-2	40/43 (93.02%)	ACAT2;ALDH2;ACADVL;...
Estrogen signaling pathway	1.66	4.82e-2	119/137 (86.86%)	TFF1;KRT14;GPER1;...
Mismatch repair	-1.58	3.86e-2	22/23 (95.65%)	RFC2;EXO1;POLD2;...
TNF signaling pathway	-1.58	4.02e-2	103/112 (91.96%)	MAPK13;IL1B;CASP10;...
Oxidative phosphorylation	-1.59	4.11e-2	93/133 (69.92%)	NDUFA7;ATP5PO;ATP6V0E2;...
NF-kappa B signaling pathway	-1.59	3.89e-2	90/104 (86.54%)	LYN;LCK;BCL2;...
Parkinson disease	-1.62	2.96e-2	176/249 (70.68%)	MAOB;VDAC3;TXN;...
IL-17 signaling pathway	-1.63	2.97e-2	84/94 (89.36%)	HSP90AB1;FOS;CXCL6;...
RNA degradation	-1.63	2.94e-2	53/79 (67.09%)	LSM7;CNOT9;MTREX;...
Rheumatoid arthritis	-1.64	2.76e-2	78/93 (83.87%)	ATP6V1D;ANGPT1;IL15;...
Graft-versus-host disease	-1.66	2.41e-2	32/42 (76.19%)	PRF1;KLRD1;IL1A;...
Prion disease	-1.66	2.45e-2	209/273 (76.56%)	NDUFA10;MAPK13;PSMB1;...
Mineral absorption	-1.68	2.04e-2	48/60 (80%)	MT1X;HEPH;ATP1B3;...
Thiamine metabolism	-1.69	1.99e-2	12/15 (80%)	ACP1;TPK1;ALPL;...
Type I diabetes mellitus	-1.70	1.74e-2	38/43 (88.37%)	HLA-DQB1;HLA-DOA;CD28;...
Epstein-Barr virus infection	-1.71	1.74e-2	189/202 (93.56%)	CCND2;MAPK9;CD19;...
Antigen processing and presentation	-1.71	1.73e-2	60/78 (76.92%)	NFYB;CD8A;CALR;...
Viral protein interaction with cytokine and cytokine re...	-1.73	1.40e-2	84/100 (84%)	CCL4;CCL8;CCR5;...
Systemic lupus erythematosus	-1.85	3.62e-3	45/135 (33.33%)	IL10;C2;GRIN2A;...
Ribosome	-1.85	4.02e-3	113/158 (71.52%)	RPS15A;RPS14;RPL12;...
Cell cycle	-1.93	2.26e-3	110/124 (88.71%)	CHEK1;E2F3;E2F4;...
Non-homologous end-joining	-1.97	1.29e-3	11/13 (84.62%)	NHEJ1;DNTT;FEN1;...
Spliceosome	-2.02	0.00e+0	101/150 (67.33%)	SNRNP27;SF3B4;CDC40;...
RNA polymerase	-2.02	0.00e+0	23/31 (74.19%)	POLR3E;POLR2F;POLR3G;...
DNA replication	-2.12	0.00e+0	34/36 (94.44%)	POLA1;RPA1;RPA3;...
Ribosome biogenesis in eukaryotes	-2.21	0.00e+0	52/108 (48.15%)	SNU13;IMP4;NOP56;...
Proteasome	-2.35	0.00e+0	44/46 (95.65%)	PSME1;PSMB9;PSMA5;...
RNA transport	-2.59	0.00e+0	128/186 (68.82%)	EIF2B2;NUP210;FUS;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H	Hide ▲
MDA-MB-231	CVCL_0062	Homo sapiens	0.01uM - 10uM	24H	Hide ▲

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H	Show ▼

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.01uM - 10uM	24H	Show ▼

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.04uM - 10uM	24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼
VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Umbilical vein

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HUVEC-C	CVCL_2959	Homo sapiens	0.01uM - 10uM	24H	Show ▼